"Therapeutic adherence is the degree to which the patient follows the doctor’s recommendations regarding doses, timing and frequency of intake of a drug for the entire duration of the therapy".
It therefore requires the patient’s agreement with – and active involvement in – the doctor’s recommendations, according to a model of therapeutic alliance. For these reasons, an inadequate adherence leads to the loss of efficacy of the pharmacological therapies, with a strong impact on the clinical outcomes and the costs of care. The analyses contained in the OsMed 2020 Report1 revealed that in Italy adherence to therapy has very low values, with a coverage percentage of less than 40%2 among patients who use drugs for the most common chronic diseases.
IBSA – a Company with a strong vocation for scientific and technological innovation – decided to use its know-how and expertise in the research and development of the "best form of drugs", that is, solutions and therapeutic formulations that are not only effective, but that also have the "right format" for the patients who have to take them every day. Valuing people by focusing on the humanization of care means precisely this: focusing attention on the concrete needs of patients, by directing research and investing in new forms of administration and delivery.